AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients with advanced non-small cell lung cancer (NSCLC) with and without previous exposure to other KRAS G12C...
Source
MedPage Today
Opens original article in a new tab
The Swiss drugmaker Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval.
A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a generation beyond.
A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.
